# Diagnosing Brain Conditions by Watching Lab-Grown Neurons Light Up > This patent describes a method to diagnose brain disorders by taking a patient's cell, turning it into a neuron, making it glow when active, and comparing its light patterns to a genetically matched healthy cell. - **Patent:** US 12736528 - **Original title:** Diagnostic methods for neural disorders - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, gene_editing, diagnostics, healthcare ## What it does The patent describes a method to diagnose neuronal conditions. It involves taking a patient's cell and converting it into a neuron. This engineered neuron is then modified to include an "optical reporter," which means it will show a light-based "optical signature" when stimulated, reflecting its electrical activity or "action potentials." To understand the effect of a specific genetic change, a control neuron is created using "genome-editing." This control neuron is genetically identical ("isogenic") to the patient's neuron, except for the single mutation being studied. By comparing the optical signature of the patient's neuron to this control, any differences can be linked to the mutation and used to diagnose a "neurodegenerative disease," such as Alzheimer's or Parkinson's. For example, a patient with suspected Parkinson's disease could have their skin cells converted into neurons, made to glow, and their activity patterns compared to an edited, healthy version of their own neuron to identify disease-related changes. ## What it does NOT cover - Does not cover diagnostic methods that rely solely on electrical measurements of neurons without an optical reporter. - Does not cover diagnosing neuronal conditions directly within a living patient's body, as it specifies "in vitro" evaluation. - Does not cover methods that use non-neuronal cells or existing neurons from a patient without converting them. - Does not cover diagnostic approaches that do not involve creating and comparing to an isogenic control cell. - Does not cover methods that detect neuronal activity using chemical or mechanical means rather than optical signals. ## The clever bit The novelty lies in creating patient-specific neurons, making them optically active, and then using genome editing to create an *isogenic* control. This allows for a highly precise comparison to see the effect of a single genetic mutation within that patient's unique genetic background. ## Real-world examples 1. Research labs studying neurodegenerative diseases like Alzheimer's or ALS 2. Drug discovery platforms for neurological disorders 3. Personalized medicine approaches for brain conditions ## Why it matters This method offers a precise way to study neurodegenerative diseases in a patient-specific manner, outside the human body. It helps researchers understand how specific genetic mutations contribute to these complex conditions. This approach could lead to more personalized diagnoses and allow for testing potential drug treatments on a patient's own cells before administering them. ## Frequently asked questions ### What does Diagnosing Brain Conditions by Watching Lab-Grown Neurons Light Up cover? This patent describes a method to diagnose brain disorders by taking a patient's cell, turning it into a neuron, making it glow when active, and comparing its light patterns to a genetically matched healthy cell. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? This method offers a precise way to study neurodegenerative diseases in a patient-specific manner, outside the human body. It helps researchers understand how specific genetic mutations contribute to these complex conditions. This approach could lead to more personalized diagnoses and allow for testing potential drug treatments on a patient's own cells before administering them. ### What does this patent NOT cover? Does not cover diagnostic methods that rely solely on electrical measurements of neurons without an optical reporter. **Full plain-English explainer:** https://patentbrief.org/patent/us/12736528/diagnostic-methods-for-neural-disorders **Original patent:** https://patents.google.com/patent/US12736528 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Diagnosing Brain Diseases by Measuring a Protein in Blood or Urine](https://patentbrief.org/patent/us/20220283184/novel-diagnostic-marker-for-creutzfeldt-jakob-disease-and-alzheimers-disease) — This patent describes a method for diagnosing brain diseases like Alzheimer's and Creutzfeldt-Jakob disease by measuring the amount of a specific protein called beta-synuclein in non-spinal fluid samples such as blood or urine. - [Checking if Brain Injury Drugs Work Using Saliva or Urine](https://patentbrief.org/patent/us/20200371093/prognostic-and-diagnostic-glycan-based-biomarkers-of-brain-damage) — This patent describes a method to determine if a drug for brain injury is effective by measuring specific sugar molecules in a patient's saliva or urine samples over time. - [How Computers Use Brain Maps to Diagnose Alzheimer's Disease](https://patentbrief.org/patent/us/12376789/raptor-testing) — A method for classifying stages of Alzheimer's disease by turning brain scan data into mathematical graphs and using machine learning to identify patterns. - [How Oligonucleotides Target C9orf72 for Brain Diseases](https://patentbrief.org/patent/us/12735703/oligonucleotide-compositions-and-methods-of-use-thereof) — This patent describes using special genetic molecules called oligonucleotides to treat brain diseases like ALS and FTD by targeting a specific gene called C9orf72. - [Detecting Alzheimer's Risk Early with a Blood Test and Brain Scan](https://patentbrief.org/patent/us/11193946/blood-biomarker-for-discerning-beta-amyloid-accumulation-in-brain) — This patent describes a two-step method to predict early Alzheimer's disease by first checking specific protein levels in a blood sample, and then, if certain markers are low, performing a brain scan to confirm amyloid beta buildup.